A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations

Authors

Siddhartha Devarakonda, Washington University School of Medicine in St. Louis
Bruna Pellini, Moffitt Cancer Center and Research Institute, Tampa
Luke Verghese, Washington University School of Medicine in St. Louis
Haeseong Park, Washington University School of Medicine in St. Louis
Daniel Morgensztern, Washington University School of Medicine in St. Louis
Ramaswamy Govindan, Washington University School of Medicine in St. Louis
Rama Suresh, Washington University School of Medicine in St. Louis
Peter Oppelt, Washington University School of Medicine in St. Louis
Maria Q. Baggstrom, Washington University School of Medicine in St. Louis
Ningying Wu, Washington University School of Medicine in St. Louis
Saiama N. Waqar, Washington University School of Medicine in St. Louis

Journal

Journal of Thoracic Disease

Publication Date

7-1-2021

Volume

13

Issue

7

First Page

4054

Last Page

4062

Document Type

Open Access Publication

DOI

10.21037/jtd-21-195

Rights and Permissions

Devarakonda S, Pellini B, Verghese L, Park H, Morgensztern D, Govindan R, Suresh R, Oppelt P, Baggstrom MQ, Wu N, Waqar SN. A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. J Thorac Dis 2021;13(7):4054-4062. doi: 10.21037/jtd-21-195

Recommended Citation

Devarakonda, Siddhartha; Pellini, Bruna; Verghese, Luke; Park, Haeseong; Morgensztern, Daniel; Govindan, Ramaswamy; Suresh, Rama; Oppelt, Peter; Baggstrom, Maria Q.; Wu, Ningying; and Waqar, Saiama N., "A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations." Journal of Thoracic Disease. 13, 7. 4054 - 4062. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/11183